Similar articles

• Synopsis of the anticoagulant and antithrombotic profile of the low molecular weight heparinoid Org 10172 in experimental models.

  Meuleman DG. Meuleman DG. Semin Thromb Hemost. 1989 Oct;15(4):370-2. doi: 10.1055/s-2007-1002732. Semin Thromb Hemost. 1989. PMID: 2479103
• Clinical use of heparin fractions, fragments, and heparinoids.

  Messmore HL Jr. Messmore HL Jr. Semin Thromb Hemost. 1985 Apr;11(2):208-12. doi: 10.1055/s-2007-1004376. Semin Thromb Hemost. 1985. PMID: 2412297 Review. No abstract available.
• Orgaran (Org 10172): its pharmacological profile in experimental models.

  Meuleman DG. Meuleman DG. Haemostasis. 1992;22(2):58-65. doi: 10.1159/000216296. Haemostasis. 1992. PMID: 1379965 Review.
• Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparin.

  Hoppensteadt D, Racanelli A, Walenga JM, Fareed J. Hoppensteadt D, et al. Semin Thromb Hemost. 1989 Oct;15(4):378-85. doi: 10.1055/s-2007-1002734. Semin Thromb Hemost. 1989. PMID: 2530633 No abstract available.
• Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis.

  Ortel TL, Gockerman JP, Califf RM, McCann RL, O'Connor CM, Metzler DM, Greenberg CS. Ortel TL, et al. Thromb Haemost. 1992 Mar 2;67(3):292-6. Thromb Haemost. 1992. PMID: 1379384